Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/07/22
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial ResultsGlobeNewsWire • 11/07/22
Mersana Therapeutics to Host Third Quarter 2022 Conference Call on November 7, 2022GlobeNewsWire • 10/31/22
Mersana Therapeutics Announces Completion of Enrollment in UPLIFT, a Single-Arm Registrational Trial of Upifitamab Rilsodotin (UpRi) in Platinum-Resistant Ovarian CancerGlobeNewsWire • 10/06/22
Mersana Therapeutics Announces Launch of Oncology FACETS, a Resource for Healthcare Providers to Advance Knowledge in Gynecologic MalignanciesGlobeNewsWire • 09/30/22
Mersana Therapeutics, Inc. (MRSN) Just Flashed Golden Cross Signal: Do You Buy?Zacks Investment Research • 08/16/22
Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/09/22
Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/08/22
Mersana Therapeutics Provides Business Update and Announces Second Quarter 2022 Financial ResultsGlobeNewsWire • 08/08/22
Mersana Therapeutics Announces Option Agreement with GSK for the Co-Development and Commercialization of XMT-2056, an Immunosynthen ADC Targeting HER2GlobeNewsWire • 08/08/22
Mersana Therapeutics to Host Second Quarter 2022 Conference Call on August 8, 2022 and Present at Upcoming ConferencesGlobeNewsWire • 08/03/22
Mersana Therapeutics Chief People Officer Carla Poulson Named One of Savoy Magazine's 2022 Most Influential Black Executives in Corporate AmericaGlobeNewsWire • 07/22/22
How Much Upside is Left in Mersana Therapeutics, Inc. (MRSN)? Wall Street Analysts Think 256%Zacks Investment Research • 07/11/22
Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/09/22
Mersana Therapeutics Provides Business Update and Announces First Quarter 2022 Financial ResultsGlobeNewsWire • 05/09/22
Mersana Therapeutics to Present Preclinical Data on XMT-1660, XMT-2056 and the Immunosynthen Platform at AACR Annual MeetingGlobeNewsWire • 04/05/22
Mersana Therapeutics to Present an Analysis from the Expansion Cohort of the Phase 1 Trial of Upifitamab Rilsodotin at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women's CancerGlobeNewsWire • 03/15/22
Mersana Therapeutics to Present at the Cowen 42nd Annual Health Care ConferenceGlobeNewsWire • 03/02/22
Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/28/22
Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 02/28/22
Mersana Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 02/28/22
Is a Surprise Coming for Mersana Therapeutics (MRSN) This Earnings Season?Zacks Investment Research • 02/24/22
Analysts Estimate Mersana Therapeutics, Inc. (MRSN) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 02/18/22